They’re deemed high-risk due to FDA compliance shifts, high chargebacks, subscription models, and lawsuit potential, posing challenges for standard processors.
They’re deemed high-risk due to FDA compliance shifts, high chargebacks, subscription models, and lawsuit potential, posing challenges for standard processors.